High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements

High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements — Trials · CancerIndex

Clinical trials

Registered studies

31 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 21
Recruiting: 11
Ph III recruiting: 0
Growth YoY: —
Industry share: 5%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04285268	Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma	withdrawn	Phase 2	0	Rutgers, The State University of New JerseyOTHER	1	Jan 30, 2026	clinicaltrials
NCT05228249	Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma	withdrawn	Phase 1	0	Fred Hutchinson Cancer CenterOTHER	1	Jan 13, 2023